This has led to the hope that similar products may be developed for hMPV, and Moderna has recently started trials into a mRNA ...

Not many people had heard of human metapneumovirus, or HPMV, until a surge of recent cases in China made headlines.

The attention being paid to a Chinese outbreak of a virus often confused with flu is a sign that respiratory infection ...

Investment analysts at Brookline Capital Management issued their FY2029 earnings estimates for shares of Moderna in a note issued to investors on Monday, January 13th. Brookline Capital Management ...

The Centers for Disease Control and Prevention is currently monitoring reports of a spike in human metapneumovirus (HMPV) in ...

Moderna advances combo vaccine for flu and COVID-19 with trials starting in March Pharmaceutical companies gear up to tackle ...

Five years on from the first news of COVID, recent reports of an obscure respiratory virus in China may understandably raise ...

The rate of infections with the flu-like human metapneumovirus (HMPV) in northern China is declining, a health official said, amid some international concern over a potential pandemic BEIJING ...

According to NAID, Moderna, the manufacturer of the Covid-19 vaccine, has just ended an early trial of an mRNA vaccine against HMPV and parainfluenza. According to respiratory virus surveillance ...

Moderna, Inc. (NASDAQ:MRNA – Get Free Report) fell 8.9% on Wednesday after UBS Group lowered their price target on the stock from $108.00 to $96.00. UBS Group currently has a buy rating on the stock.

This has led to the hope that similar products may be developed for hMPV, and Moderna has recently started trials into a mRNA hMPV vaccine. There are no treatments that have been clearly ...